PURPOSE: To obtain estimates of human normal-organ radiation doses of ¹⁸F-SKI-249380, as a prerequisite step towards first-in-human trial. ¹⁸F-SKI-249380 is a first-of-its-kind PET tracer for imaging the in vivo pharmacokinetics of dasatinib, an investigational targeted therapy for solid malignancies. PROCEDURES: Isoflurane-anesthetized mice received tracer dose via tail vein. Organ time-integrated activity coefficients, fractional urinary and hepatobiliary excretion, and total-body clearance kinetics were derived from PET data, with allometric extrapolation to the Standard Man anatomic model and normal-organ-absorbed dose calculations using OLINDA/EXM software. RESULTS: The human effective dose was 0.031 mSv/MBq. The critical organ was the upper large intestine, with a dose equivalent of 0.25 mSv/MBq. A 190-MBq administered activity of ¹⁸F-SKI-249380 is thus predicted to expose an adult human to radiation doses generally comparable to those of routinely used diagnostic radiopharmaceuticals. CONCLUSIONS: Animal-based human dose estimates support first-in-human testing of ¹⁸F-SKI-249380.
PURPOSE: To obtain estimates of human normal-organ radiation doses of ¹⁸F-SKI-249380, as a prerequisite step towards first-in-human trial. ¹⁸F-SKI-249380 is a first-of-its-kind PET tracer for imaging the in vivo pharmacokinetics of dasatinib, an investigational targeted therapy for solid malignancies. PROCEDURES: Isoflurane-anesthetized mice received tracer dose via tail vein. Organ time-integrated activity coefficients, fractional urinary and hepatobiliary excretion, and total-body clearance kinetics were derived from PET data, with allometric extrapolation to the Standard Man anatomic model and normal-organ-absorbed dose calculations using OLINDA/EXM software. RESULTS: The human effective dose was 0.031 mSv/MBq. The critical organ was the upper large intestine, with a dose equivalent of 0.25 mSv/MBq. A 190-MBq administered activity of ¹⁸F-SKI-249380 is thus predicted to expose an adult human to radiation doses generally comparable to those of routinely used diagnostic radiopharmaceuticals. CONCLUSIONS: Animal-based human dose estimates support first-in-human testing of ¹⁸F-SKI-249380.
Authors: Feng R Luo; Zheng Yang; Amy Camuso; Richard Smykla; Kelly McGlinchey; Krista Fager; Christine Flefleh; Stephen Castaneda; Ivan Inigo; David Kan; Mei-Li Wen; Robert Kramer; Anne Blackwood-Chirchir; Francis Y Lee Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Paul Workman; Eric O Aboagye; Yuen-Li Chung; John R Griffiths; Rachel Hart; Martin O Leach; Ross J Maxwell; Paul M J McSheehy; Pat M Price; Jamal Zweit Journal: J Natl Cancer Inst Date: 2006-05-03 Impact factor: 13.506
Authors: Darren R Veach; Mohammad Namavari; Nagavarakishore Pillarsetty; Elmer B Santos; Tatiana Beresten-Kochetkov; Caryl Lambek; Blesida J Punzalan; Christophe Antczak; Peter M Smith-Jones; Hakim Djaballah; Bayard Clarkson; Steven M Larson Journal: J Med Chem Date: 2007-10-23 Impact factor: 7.446
Authors: George D Demetri; Patricia Lo Russo; Iain R J MacPherson; Ding Wang; Jeffrey A Morgan; Valerie G Brunton; Prashni Paliwal; Shruti Agrawal; Maurizio Voi; T R Jeffry Evans Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Devendra K Hiwase; Verity Saunders; Duncan Hewett; Amity Frede; Stephanie Zrim; Phuong Dang; Laura Eadie; L Bik To; Junia Melo; Sharad Kumar; Timothy P Hughes; Deborah L White Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Faye M Johnson; Shruti Agrawal; Howard Burris; Lee Rosen; Navneet Dhillon; David Hong; Anne Blackwood-Chirchir; Feng R Luo; Oumar Sy; Sanjeev Kaul; Alberto A Chiappori Journal: Cancer Date: 2010-03-15 Impact factor: 6.860